Private finance: Exciva, VarmX, ShouTi, Cardisio, Anticancer Bioscience

China: Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, has secured an additional Rmb68.4m (US$10.6m) from new Chinese investors. The seed extension was led by Three Rivers Capital, which joins existing private Chinese investors. The total raised in the seed round is now over US$31m. Proceeds will be mainly used to accelerate…

You must be a HMI Subscriber to view this content.

Subscribe Now »